Back to search results

A Study of AZD3974 in Healthy Participants

This study is looking for healthy volunteers, aged 18 to 55, to help us understand a new oral solution called AZD3974. We want to learn about its safety, how well your body tolerates it, and how it moves through your system (pharmacokinetics). Some participants will receive AZD3974, while others will receive a placebo (an inactive substance). The main goal is to track any side effects or serious problems that might occur. This study includes people of Japanese and Chinese descent to see if there are any differences. The current status of this study is unclear.

Study design
This is a randomized, single-blind, placebo-controlled study with a planned enrollment of 176 healthy participants. It is divided into two parts: Part A (single dose) and Part B (multiple doses).
What's involved
You would have a screening period of up to 28 days, a dosing session where you receive the study intervention, and then a follow-up period of 7 days after your last dose.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 7 days after their last dose, or up to 14 days in some parts of the study, to monitor for adverse events.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07290283

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants

Recruiting
PHASE1Ages 18–55InterventionalTreatment
AstraZeneca
~176 participants
Updated 2026-07-31 on ClinicalTrials.gov
What's tested:AZD3974Placebo

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Measured over Part A: Upto Day 7; Part A1 Cohort 3: Upto Day 10; Part B: Upto Day 14

Conditions

Healthy Participants

Explore related trials

Healthy Participants

Where it's being run

2 sites across 2 states
California1
Maryland1

Who to contact

AstraZeneca Clinical Study Information Center
[email protected]
1-877-240-9479
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Healthy male and female (of non-childbearing potential) participants with suitable veins for cannulation or repeated venipuncture at the Screening Visit.
All females must have a negative pregnancy test. Females of non-childbearing potential must be confirmed via post-menopausal status or documentation of irreversible surgical sterilization at the Screening Visit.
Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods.
Have a body mass index between 18 and 32 kg/m2 inclusive and weigh at least 50 kg at Screening.
For healthy Japanese cohorts (Part A2 and Part B2): healthy male and female participants are to be Japanese (eg, natives of Japan or Japan Americans), defined as having both parents and 4 grandparents who are Japanese. This includes second and third generation participants of Japanese descent whose parents or grandparents are living in a country other than Japan.
For healthy Chinese cohort (Part A3): healthy male and female Chinese participants for whom both parents and 4 grandparents are Chinese. This includes second and third generation participants of Chinese descent whose parents or grandparents are living in a country other than China.

Exclusion

History of any clinically important disease or disorder which, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
Any abnormal laboratory values, vital signs, or any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results.
Any positive result on Screening for serum hepatitis B and C viruses and human immunodeficiency virus.
Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12 lead electrocardiography at Screening and/or admission to the Clinical Unit .
Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.
Positive screen for drugs of abuse, or alcohol, or cotinine.
History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity.
Participants who have previously received AZD3974.

What this trial measures

  • Number of participants with adverse events (AEs) and serious adverse events (SAEs)Part A: Upto Day 7; Part A1 Cohort 3: Upto Day 10; Part B: Upto Day 14

    To assess the safety and tolerability of AZD3974 following oral administration of single and multiple ascending doses in healthy participants, including Chinese and Japanese participants